DelveInsight recently conducted an in-depth MASH Market Size and Share Assessment to help a pharmaceutical client understand the ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Gilead Sciences, Inc. GILD announced positive data from its ongoing phase I study evaluating pipeline candidate, lenacapavir.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...

Gilead presented the data at the Conference on Retroviruses and Opportunistic Infections (CROI 2025). Image credit: Shutterstock / Sundry Photography Gilead is set to launch a Phase III trial of its ...

Despite recent negativity, several stocks, including Verizon Communications, Gilead Sciences, and Alibaba, have shaken off ...

A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...

The cornea is the clear, outermost layer of the eye. Its outer border, the limbus, contains a large volume of healthy stem ...

Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply ...